Allergic contact dermatitis because of topical use of 5‐fluorouracil (Efudix<sup>®</sup> cream)

Meijer, Berrie; Spek, Flora B. de Waard‐van der

doi:10.1111/j.1600-0536.2007.01079.x

Cited by 27 publications

(18 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This might be explained by co-administered oxaliplatin as stated. 5-Fluorouracil is used for cutaneous diseases such as psoriasis and actinic keratoses, and an irritant contact dermatitis is frequently seen [22-25]. This might be counted as hypersensitivity.…”

Section: Discussionmentioning

confidence: 99%

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS

Kadoyama

Kuwahara

Yamamori

et al. 2011

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundPreviously, adverse event reports (AERs) submitted to the US Food and Drug Administration (FDA) database were reviewed to confirm platinum agent-associated hypersensitivity reactions. The present study was performed to confirm whether the database could suggest the hypersensitivity reactions caused by anticancer agents, paclitaxel, docetaxel, procarbazine, asparaginase, teniposide, and etoposide.MethodsAfter a revision of arbitrary drug names and the deletion of duplicated submissions, AERs involving candidate agents were analyzed. The National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 was applied to evaluate the susceptibility to hypersensitivity reactions, and standardized official pharmacovigilance tools were used for quantitative detection of signals, i.e., drug-associated adverse events, including the proportional reporting ratio, the reporting odds ratio, the information component given by a Bayesian confidence propagation neural network, and the empirical Bayes geometric mean.ResultsBased on 1,644,220 AERs from 2004 to 2009, the signals were detected for paclitaxel-associated mild, severe, and lethal hypersensitivity reactions, and docetaxel-associated lethal reactions. However, the total number of adverse events occurring with procarbazine, asparaginase, teniposide, or etoposide was not large enough to detect signals.ConclusionsThe FDA's adverse event reporting system, AERS, and the data mining methods used herein are useful for confirming drug-associated adverse events, but the number of co-occurrences is an important factor in signal detection.

show abstract

Section: Discussionmentioning

confidence: 99%

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS

Kadoyama

Kuwahara

Yamamori

et al. 2011

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…There have been increasing reports of allergic contact dermatitis to 5-FU (Meijer & de Waard-van der Spek, 2007) and sparse reports of dysgeusia (Han & Youker, 2011), hyperpigmentation, hypopigmentation, onycholysis, onychodystrophy, hypertrophic scarring, hair regrowth, and bullous pemphigoid (Goette, 1981). The inflammatory adverse effects of 5-FU typically begin within 5-10 days of treatment and remain localized to the treatment area.…”

Section: Discussionmentioning

confidence: 99%

“…It usually elicits an irritant contact dermatitis at the application site and can uncommonly cause an allergic contact dermatitis (Meijer & de Waard-van der Spek, 2007). It usually elicits an irritant contact dermatitis at the application site and can uncommonly cause an allergic contact dermatitis (Meijer & de Waard-van der Spek, 2007).…”

Section: Introductionmentioning

confidence: 99%

Generalized pustular drug eruption caused by topical 5-fluorouracil

Nemer

Solus²,

Schaffer³

et al. 2017

Dermatologic Therapy

View full text Add to dashboard Cite

“…Local inflammation may be increased when preparations are applied to mucosal surfaces, which may result in more serious reactions such as blister formation, ulceration and crusting. Allergic contact dermatitis, both to 5-FU and vehicle components, has also been reported [10]. Systemic adverse reactions are exceedingly rare, except as reported in the case of dihydropyrimidine dehydrogenase enzyme deficiency, although peripheral neuropathy has been reported in 1 patient with normal enzyme levels [11].…”

Section: Topical 5-fluorouracilmentioning

confidence: 99%

Topical Antineoplastic Agents in the Treatment of Mucocutaneous Diseases

Grossberg

Gaspari

2011

Topical Applications and the Mucosa

View full text Add to dashboard Cite

Topical antineoplastic agents have a well-established role in the treatment of several dermatological conditions. Their use in the treatment of mucosal skin disease also has gained increasing recognition. Topical 5-fluorouracil (5-FU), an antimetabolite, and imiquimod, an immunomodulatory agent with antitumor properties, are the two principal topical antineoplastic agents used in the treatment of mucocutaneous diseases. Although the vast majority of their mucosal uses are currently not approved by the Federal Drug Administration, there are numerous case series, open-label studies and randomized controlled trials supporting their uses in the treatment of mucocutaneous diseases. Both topical 5-FU and imiquimod have been successfully utilized in the treatment of a wide range of mucosal diseases, including actinic cheilitis, Bowen's disease of the anal and vulvar mucosa, and genital and perianal condyloma. Reports of their uses in the treatment of mucocutaneous diseases indicate that these agents can be safely administered, though adverse effects such as local inflammation may be augmented when these agents are applied to mucosal surfaces. Additionally, locally acting intralesional chemotherapeutic agents, such as bleomycin and interferon, have well-defined applications in the treatment of mucosal skin diseases such as condyloma acuminata. As further studies are conducted, these topical and intralesional neoplastic agents, in addition to emerging agents that are in various stages of development, such as Toll-like receptor 9 agonists and ingenol mebutate, may play an increasingly important role in the future treatment of mucocutaneous diseases.

show abstract

Allergic contact dermatitis because of topical use of 5‐fluorouracil (Efudix^® cream)

Cited by 27 publications

References 16 publications

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS

Generalized pustular drug eruption caused by topical 5-fluorouracil

Topical Antineoplastic Agents in the Treatment of Mucocutaneous Diseases

Contact Info

Product

Resources

About

Allergic contact dermatitis because of topical use of 5‐fluorouracil (Efudix® cream)

Cited by 27 publications

References 16 publications

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS

Hypersensitivity reactions to anticancer agents: Data mining of the public version of the FDA adverse event reporting system, AERS

Generalized pustular drug eruption caused by topical 5-fluorouracil

Topical Antineoplastic Agents in the Treatment of Mucocutaneous Diseases

Contact Info

Product

Resources

About

Allergic contact dermatitis because of topical use of 5‐fluorouracil (Efudix^® cream)